ProteusDx™ Receives SEC Qualification for Reg A+ Offering to Commercialize AI-Enhanced Capsule Endoscopy Platform

SEC qualification enables ProteusDx™ to raise capital, drive FDA clearances, and accelerate commercialization of AI-enhanced GI diagnostics

DANVILLE, CA, UNITED STATES, September 16, 2025 /EINPresswire.com/ -- ProteusDx™ by FirstVitals^®, an innovator in AI-enhanced capsule endoscopy and targeted drug delivery, today announced that the U.S. Securities and Exchange Commission (SEC) has qualified its Regulation A+ offering, enabling the company to raise capital from both accredited and retail investors.

This SEC qualification marks a significant milestone in the company’s mission to transform gastrointestinal (GI) health through advanced, patient-friendly diagnostics and therapeutics. The Regulation A+ framework allows ProteusDx™ by FirstVitals^® to broaden access to its investment opportunity while pursuing key clinical, regulatory, and commercialization initiatives.

Strategic Use of Funds
Proceeds from the offering are intended to accelerate:
• FDA Clearance Efforts: Advancing regulatory submissions for the ProteusDx™ capsule endoscopy platform and AI-assisted interpretation tools.
• Commercialization: Launching initial pilots in physician practices and expanding awareness of non-invasive capsule endoscopy for patients.
• AI Innovation: Enhancing proprietary modules such as Lesion Mapping, Bleed Detection, and Inflammation Scoring Metrics.
• ProteusTx™ Development: Expanding into targeted drug delivery applications, beginning with equine gastric ulcers and extending into human therapeutics.

Leadership Commentary
"Receiving SEC qualification for our Regulation A+ offering is a transformative milestone for the ProteusDx™ platform," said Ernie G. Lee, Founder & CEO of FirstVitals. "This approval enables us to invite a broader community of investors to join our mission of making GI diagnostics and treatments more accessible, accurate, and patient-friendly. The capital raised will support our FDA roadmap, commercialization efforts, and long-term vision of targeted capsule therapeutics."

Investment Access
Interested investors can learn more and participate in the qualified offering at: www.firstvitals.com. Company website: www.proteusdx.com

About ProteusDx™ by FirstVitals^®

ProteusDx™ by FirstVitals^® is an advanced, AI-powered capsule endoscopy platform redefining how gastrointestinal health is assessed and managed. The platform delivers a patient-friendly alternative to invasive procedures, enabling accurate GI visualization, early detection of lesions, ulcers and polyps, and long-term monitoring. Through the integration of artificial intelligence, ProteusDx™ enhances diagnostic accuracy while supporting providers with actionable insights.

Future innovations include ProteusTx™, a targeted drug delivery capsule, and expansion into veterinary applications, addressing gastric ulcers in horses and GI health in companion pets. Anchored within the Test2Treat ecosystem, ProteusDx™ by FirstVitals^® is committed to improving accessibility, accuracy, and patient outcomes while driving investor value through scalable technology and future regulatory milestones.

For more information, visit www.proteusdx.com
Media Contact
Name: anthony.voorhies@firstvitals.com
Email: press@firstvitals.com
Phone: +1-800-922-8844

Disclaimer: This press release does not constitute an offer to sell or a solicitation of an offer to buy securities. The offering is made only by means of the offering circular qualified by the SEC. Investors should read the offering circular and related risk factors before investing.

AJ Daly
ProteusDx™
investors@firstvitals.com

From science fiction to today's reality. ProteusDx™ is here.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.